Tsumura & (4540) Fundamentals 2026 — P/E 10.3x, Revenue Analysis | SniperIQ
Tsumura & (4540) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥287.8B, trading at ¥3861.00 on the JPX. This SniperIQ fundamentals page covers Tsumura &'s valuation (P/E 10.3x, P/B 0.9x), profitability (net margin 14.6%), revenue (¥192.6B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tsumura &'s market cap?
Tsumura & (4540) has a market capitalization of approximately ¥287.8B, trading at ¥3861.00 on the JPX. Market cap moves with the live share price.
What is Tsumura &'s P/E ratio?
Tsumura &'s trailing twelve-month P/E ratio is 10.3x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tsumura &?
Tsumura & runs a net profit margin of 14.6%, a gross margin of 47.5%, and an operating margin of 18.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tsumura & generate?
Tsumura & reported revenue of ¥192.6B for fiscal year 2026, with net income of ¥28.1B and earnings per share (EPS) of 376.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tsumura & pay a dividend?
Tsumura & offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tsumura & financially healthy?
Tsumura & carries a debt-to-equity ratio of 0.42x and a current ratio of 4.19x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tsumura & a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tsumura & (4540) the key facts are: market cap ¥287.8B, P/E 10.3x, revenue ¥192.6B, 52-week range 3418-4403. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tsumura &'s full fundamentals live
Get Tsumura &'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.